Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q1 FY23 results · Apr–Jun 2022
Tatva Chintan Pharma Chem reported revenue from operations of ₹88.40 crore (down 17.3% from Q1 FY22) and net profit of ₹9.80 crore (down 57.7% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 88.40 | 106.83 | −17.3% | 98.53 | −10.3% |
| Other income | 1.83 | 2.97 | −38.4% | 0.35 | +416.7% |
| Total income | 90.23 | 109.80 | −17.8% | 98.89 | −8.8% |
| Profit before tax | 13.70 | 24.26 | −43.6% | 18.98 | −27.8% |
| Net profit for the period | 9.80 | 23.15 | −57.7% | 17.51 | −44.0% |
| EPS, basic (₹) | 4.42 | 11.52 | not comparable | 7.90 | −44.1% |
| Net margin (%) | 11.1 | 21.7 | 17.8 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 86.06 | 107.65 | −20.1% | 101.88 | −15.5% |
| Other income | 1.83 | 2.77 | −34.0% | 1.19 | +54.0% |
| Total income | 87.89 | 110.42 | −20.4% | 103.07 | −14.7% |
| Profit before tax | 11.98 | 24.98 | −52.1% | 19.96 | −40.0% |
| Net profit for the period | 8.50 | 23.96 | −64.5% | 18.89 | −55.0% |
| EPS, basic (₹) | 3.83 | 11.93 | not comparable | 8.52 | −55.0% |
| Net margin (%) | 9.9 | 22.3 | 18.5 |
Consolidated
- Filed with BSE
- 26 Jul 2022, 12:41 IST
- Board meeting
- 25 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Jul 2022, 12:41 IST
- Board meeting
- 25 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE